If you are a student, recent graduate or alumni interested in exploring a career in the biotechnology, pharmaceutical and life sciences industries, you are in the right place! Register today to start your job search and be contacted by employers nationwide looking for you! It only takes a few minutes and you will be on your way to the perfect job!
Friday, February 05, 2010
Already a hub for racing and distribution, Hendricks County has begun to make its mark in the biotechnology and medical industry, too.
Two separate announcements in the past month, with a third planned in the coming weeks, could bring an estimated 200 jobs and an investment of nearly $50 million to the county.Read Full Article
Wednesday, January 27, 2010
Elona Biotechnologies wants to build an insulin manufacturing plant in Greenwood, creating up to 70 jobs that would pay an average of $55,000. The contract research and development company confirmed Tuesday it plans to make generic human insulin and would invest more than $25 million over 10 years in the 50,000-square-foot site on Greenwood’s east side. Elona is seeking $6.5 million in incentives from Greenwood.Read Full Article
Wednesday, November 18, 2009
A new biotech company has established its headquarters in Indianapolis. Aarden Pharmaceuticals is focusing on a technology developed in the laboratory of Dr. Zhong-Yin Zhang, Robert A. Harris Professor and Chairman of Biochemistry and Molecular Biology at Indiana University School of Medicine, and an internationally recognized expert in the field of protein tyrosine phosphatases (PTPs).
Dr. Zhang’s chemistry breakthrough allows drugs that block PTPs to be made for the first time, opening the door to new treatments for a variety of tough diseases.
Aarden’s tuberculosis (TB) drug, I-A09, is currently in pre-clinical development. Independent studies are now running concurrently at two major universities to demonstrate the effectiveness of I-A09 for TB in animal models.Read Full Article
Tuesday, October 27, 2009
PDS Biotechnology Corporation has announced the completion of GLP toxicology studies of its lead HPV-cancer product. PDS Biotechnology is located in the Lakefront Campus of Ivy Tech Community College in Lawrenceburg and applies the company’s proprietary platform Versamune™ nanotechnology to the development of safe and potent immunotherapies to prevent and treat cancer and diseases caused by infectious agents.
Ivy Tech’s available lab space was instrumental in the biotech firm’s decision to locate to Lawrenceburg, which the company termed an ideal location due to its proximity to Louisville, Cincinnati and Indianapolis.Read Full Article
Thursday, October 15, 2009
PDS Biotechnology Corporation today
announced that the company has completed GLP toxicology studies of its lead
HPV-cancer product. The studies, which included pharmacokinetic (PK) and
adsorption, bio-distribution and excretion (ADE) studies in addition to the
evaluation of toxicity, all demonstrated a very safe profile of the drug and
PDS Biotech’s platform Versamune((TM)) technology. No signs of toxicity were
observed at the highest doses evaluated, significantly higher than the
effective doses observed in preclinical studies. The studies also provided
further confirmation of the technology’s mechanism of action and efficient
uptake by the immune system.
Dr. Frank Bedu-Addo, PDS Biotechnology’s President and CEO, stated that this
was a pivotal study in the company’s progress towards confirming the
technology’s safety profile and evaluation in human clinical trials next year
to treat cervical cancer. He also stated that “the high safety and efficacy
that the technology has demonstrated will also enable the company to initiate
discussions with prospective corporate partners to start developing the
company’s infectious disease drugs which will target widespread diseases such
as hepatitis, HIV, influenza and herpes.“Read Full ArticleRead Full Article
Wednesday, October 07, 2009
Indiana took another step forward as a leader in biotechnology innovation with a major announcement at Purdue Research Park Wednesday. Dow AgroSciences will be expanding its Indiana operations into new research facilities at the park.
Purdue University President France Cordova made the announcement, explaining that “Dow AgroSciences will occupy 15,000 square feet of research and office space that will support thirty researchers in the newly built Herman and Heddy Kurz Purdue Technology Center. And Dow AgroSciences will be the exclusive tenant of a 6,000 square foot greenhouse complex that Purdue Research Park will construct.”
The $2.2 million greenhouse research center gets a boost from a grant for development costs from the Indiana Economic Development Corporation. Mitch Roob, the CEO of IEDC and Indiana’s Secretary of Commerce, made it clear why the state supports the project. “There is no more important company to the long term future of the state of Indiana than Dow AgroSciences.”Read Full Article
Sunday, September 20, 2009
Indianapolis researchers are using a Small Business Innovation Research grant to develop technology which could alleviate negative side effects during stem cell transplants for cancer patients.
General BioTechnology will use a $350,000 grant from the state to further develop and test its Advanced CryoTechnology Cell Washing Device. The Indiana grant accompanies federal funding of more than $1 million to develop the device for clinical use. The company plans to begin a pilot safety study of the technology in the first quarter of 2010 with Indiana University before a larger clinical trial later in the year continuing with the Fred Hutchison Cancer Research Center in Seattle, Wash., and Indiana University.Read Full Article
Thursday, August 27, 2009
INDIANAPOLIS (Aug. 27, 2009) - Indianapolis researchers are using a Small Business Innovation Research grant to develop technology which could alleviate negative side effects during stem cell transplants for cancer patients.
General BioTechnology will use a $350,000 grant from the state to further develop and test its Advanced CryoTechnology Cell Washing Device. The Indiana grant accompanies federal funding of more than $1 million to develop the device for clinical use. The company plans to begin a pilot safety study of the technology in the first quarter of 2010 with Indiana University before a larger clinical trial later in the year continuing with the Fred Hutchison Cancer Research Center in Seattle, Wash., and Indiana University.Read Full Article
Thursday, July 16, 2009
INDIANAPOLIS (WISH) - Former Congressman Dick Gephardt sat on a panel leading the conversation on health care and the importance of Biotech Companies in Indiana on Tuesday.
Earlier on Daybreak, Gephardt talked about his new role as president of the Council for American Medical Innovation.Read Full Article
Wednesday, July 15, 2009
A start-up developer of nanosurfaced implants and nanostructured biomaterials at the Purdue Research Park in West Lafayette will create up to 42 research and development jobs over the next few years. Nanovis LLC has begun initial testing of a bone regeneration technology with the help of a $2 million grant from the state’s 21st Century Research and Technology Fund, but will need to expand its work force as the company moves into commercialization. Nanovis says its technology represents a potential breakthrough for sufferers of osteoporosis and other bone disorders.Read Full Article
Phoenix • Tucson • Palm Springs • Sacramento • San Diego • San Francisco • San Jose • Denver • Jacksonville • Miami • Orlando • Tampa • Atlanta • Chicago • Indianapolis • Kansas City • Louisville • New Orleans • Boston • Baltimore • Detroit • Grand Rapids • Minneapolis • Charlotte • Raleigh • Omaha • Atlantic City • Las Vegas • Reno • Buffalo • New York City • Cincinnati • Cleveland • Toledo • Tulsa • Portland • Philadelphia • Pittsburgh • Myrtle Beach • Memphis • Nashville • Austin • Dallas • Houston • San Antonio • Salt Lake City • Richmond • Seattle • Spokane
